All In Biotech

Drug Trial Radar · NCT04594369

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study

Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,767 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,767

Actual

Start

Dec 1, 2020

Primary completion

Oct 28, 2024

Study completion Oct 28, 2024

Sponsor

Lead sponsor
Insmed IncorporatedIndustry
Sponsor type
Industry
First posted
Oct 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.

Conditions

  • Non-Cystic Fibrosis Bronchiectasis

Interventions

  • Brensocatib 10 mgDrug

    Oral tablet.

  • Brensocatib 25 mgDrug

    Oral tablet.

  • PlaceboDrug

    Brensocatib-matching oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Pulmonary Exacerbations (PEs)Time frame: Up to Week 52

Locations

373 sites in 36 countries. Site status is shown where the registry gives one.

  • USA013

    Birmingham, Alabama

  • USA080

    Conway, Arkansas

  • USA044

    Little Rock, Arkansas

  • USA104

    Fresno, California

  • USA055

    Los Angeles, California

  • USA029

    Newport Beach, California

  • USA102

    Northridge, California

  • USA022

    Palm Springs, California

  • USA024

    Sacramento, California

  • USA035

    San Diego, California

  • USA078

    Santa Barbara, California

  • USA027

    Ventura, California

  • USA075

    Denver, Colorado

  • USA017

    Farmington, Connecticut

  • USA001

    Washington D.C., District of Columbia

  • USA015

    Clearwater, Florida

  • USA076

    Gainesville, Florida

  • USA082

    Jacksonville, Florida

  • USA039

    Kissimmee, Florida

  • USA072

    Leesburg, Florida

  • USA037

    Miami, Florida

  • USA019

    Miami Lakes, Florida

  • USA049

    Naples, Florida

  • USA052

    Orlando, Florida

  • USA103

    Plantation, Florida

  • USA084

    Sarasota, Florida

  • USA089

    St. Petersburg, Florida

  • USA074

    St. Petersburg, Florida

  • USA120

    Tampa, Florida

  • USA012

    Atlanta, Georgia

  • USA053

    Augusta, Georgia

  • USA073

    Chicago, Illinois

  • USA061

    Maywood, Illinois

  • USA115

    Hammond, Indiana

  • USA063

    Iowa City, Iowa

  • USA031

    Kansas City, Kansas

  • USA020

    New Orleans, Louisiana

  • USA051

    New Orleans, Louisiana

  • USA003

    Baltimore, Maryland

  • USA079

    Boston, Massachusetts

Showing 40 of 373 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.